Historical Stock Price
ETFs Holding APLS »    Stock Splits Calendar »
Video: Compound Annual Growth Rate (CAGR) Definition


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Date Open High Low Close Volume
12/02/2022 $50.13 $51.70 $49.26 $50.63 889.80K
12/05/2022 $50.38 $50.73 $48.41 $49.38 1.01M
12/06/2022 $49.32 $49.47 $46.81 $46.88 1.14M
12/07/2022 $46.58 $48.12 $46.57 $47.52 663.30K
12/08/2022 $47.70 $50.54 $46.75 $50.36 1.34M
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic compounds to treat diseases through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Pegcetacoplan targets C3, the central protein of the complement cascade. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.
APLS historical stock prices picture
Apellis Pharmaceuticals (APLS) has the following price history information. Looking back at APLS historical stock prices for the last five trading days, on December 02, 2022, APLS opened at $50.13, traded as high as $51.70 and as low as $49.26, and closed at $50.63. Trading volume was a total of 889.80K shares. On December 05, 2022, APLS opened at $50.38, traded as high as $50.73 and as low as $48.41, and closed at $49.38. Trading volume was a total of 1.01M shares. On December 06, 2022, APLS opened at $49.32, traded as high as $49.47 and as low as $46.81, and closed at $46.88. Trading volume was a total of 1.14M shares. On December 07, 2022, APLS opened at $46.58, traded as high as $48.12 and as low as $46.57, and closed at $47.52. Trading volume was a total of 663.30K shares. On December 08, 2022, APLS opened at $47.70, traded as high as $50.54 and as low as $46.75, and closed at $50.36. Trading volume was a total of 1.34M shares.

APLS Historical Stock Prices By Date:

APLS historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Apellis Pharmaceuticals shares, starting with a $10,000 purchase of APLS, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/10/2017
End date: 12/08/2022
Start price/share: $14.00
End price/share: $50.36
Dividends collected/share: $0.00
Total return: 259.71%
Average Annual Total Return: 28.66%
Starting investment: $10,000.00
Ending investment: $35,967.75
Years: 5.08
Date Close
12/02/2022$50.63
12/05/2022$49.38
12/06/2022$46.88
12/07/2022$47.52
12/08/2022$50.36
APLS is categorized under the Healthcare sector; below are some other companies in the same sector:

APPY Historical Stock Prices
APRI Historical Stock Prices
APVO Historical Stock Prices
AQB Historical Stock Prices
AQXP Historical Stock Prices
ARA Historical Stock Prices
ARAY Historical Stock Prices
ARDM Historical Stock Prices
ARDX Historical Stock Prices
ARGS Historical Stock Prices

Also explore: APLS shares outstanding history

Email EnvelopeFree APLS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

APLS Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.